Heating Things Up…While Keeping Our Cool!
Heating Things Up…While Keeping Our Cool!
 Heating Things Up…While Keeping Our Cool!
STM Newsletter
- April 2022 -
Annual Meeting
Join your colleagues May 1-4, 2022 for the virtual annual meeting! 
Registration is NOW OPEN for the virtual annual meeting which will be taking place in Gather.town! Click HERE to register.
Online Program HERE.
Please share this email with your colleagues, students, and anyone else  you might think is interested! 
Speakers,
Check the time of your presentation (in the detailed instructional email sent by the organziers on April 6)!
Please note the following deadlines:
- Final video presentation submission deadline: April 22, 2022 
- Register for the annual meeting by April 22 to confirm your spot in the program.
- Email a high resolution headshot, your full name and credentials to stm@allenpress.com by April 15

Session Topics Include:
- 2 Keynote Speakers
- Ablation
- HIPEC
- Computational Modeling
- Immunology and thermal medicine
- Magnetic hyperthermia
- Nanoparticles
- Treatment planning
- Cryotherapies
- Clinical hyperthermia outcomes
- Thermal modalities for treating brain tumors
- Focused ultrasound
- Grant writing and job searches
Keynote Speakers:
Dr. Catherine Bollard, MBChB, MD, FRACP, FRCPA, Bosworth Chair for Cancer Biology and Director of the Center for Cancer and Immunology Research at Children’s National Hospital. Dr. Bollard is a world-renowned pediatric hematologist-oncologist with bench and translational research focuses on improving outcomes for patients after hematopoietic stem cell transplantation and on the development of novel cell therapies for cancer and virus-associated diseases.

Dr. Alda Tam, MD, MBA, FRCPC, FSIR, Professor in the Department of Interventional Radiology at the University of Texas MD Anderson Cancer Center. Dr. Tam is an inducted fellow of the Society of Interventional Radiology and maintains an active interventional radiology practice with involvement in both translational and clinical trials.

And there's more!
“Mock Study Section - a learning tool for grant writing.” 
Dr. Mark Dewhirst is offering a special seminar on grant writing entitled: “Mock Study Section - a learning tool for grant writing.” In order to participate in the session you must register for it separately (it is free), and come prepared to engage and learn! Register HERE.
**Registration for this Mock Study Section is limited 50 people and will close on April 18. You must be registered for the Annual Meeting to attend.**
STM 2022 Awards - Celebrate Your Colleagues!
Join us in congratulating the winners of the 2022 STM Awards, and please join us at STM 2022 where they will be giving their award presentations. Register for the annual meeting HERE.
2022 J. Eugene Robinson Award Winner (Clinical/Medical)
Dr. Mark Hurwitz MD, FASTRO, FACRO
Professor and Chair,
Department of Radiation Medicine
New York Medical College
Director,
Department of Radiation Medicine
Westchester Medical Center Health Network
The J. Eugene Robinson Award is presented each year to an investigator who has made outstanding contributions to hyperthermic oncology. This lecture is to acknowledge the work of J. Eugene Robinson who was a pioneer in hyperthermic research for 20 years. He first used hyperthermia as an anti-cancer agent in the late 1960's and continued his investigations in various areas related to hyperthermia including thermal dose and time-temperature relationships. This award is given to investigators in each of the three main disciplines in Thermal Medicine (physics, biology and clinical/medicine) in a rotating fashion each year. For the 2022 Award we chose from the Clinical/Medical discipline.
2022 William C. Dewey Award Winner
Dr. Sharon S. Evans, PHD
Department of Immunology
Roswell Park Comprehensive Cancer Center
Buffalo, NY
The William C. Dewey Award is presented every other year to an investigator who has contributed in a significant way to the mentorship and training of new investigators in the field of thermal medicine. This lecture is named in honor of Dr. Bill Dewey who trained many leaders in our field in all three disciplines (physics, biology and clinical/medical). His emphasis on making hyperthermia treatment a quantifiable therapy with a defined method for performing thermal dosimetry has stood the test of time and has influenced how hyperthermia and thermal ablation are practiced today.
2022 STM Scholar-in-Training Awards
Please also help us celebrate the winners of our 2022 SITA Awards!
These members will present their talks at the 2022 STM Annual Meeting and will receive a $250 cash award. 
Scholar-in-Training Award recipients are based upon a competitive evaluation of their submitted abstracts
and Scholar-in-Training Award applications.

Paola Tello - The impact of high thermal dose in patients treated with postoperative re-irradiation and hyperthermia for locoregional recurrent breast cancer
Jacob Medina - Photothermal Therapy of Melanoma with anti-CD137 Coated Prussian Blue Nanoparticles
Pragya Gupta - Treatment modeling and planning strategies for clinical interstitial ultrasound thermal ablation of focal prostate cancer
Tori Chanenchuk - Magnetic iron oxide nanoparticles induce an immune response, DNA damage and apoptosis in a syngeneic rodent glioblastoma model
Varun Sadaphal - Feasibility of heating metal implants with alternating magnetic fields (AMF) in scaled up models
Emily Engelbrecht-Wiggans - Concurrent superficial hyperthermia and intensity-modulated proton therapy for recurrent breast cancer
Muhammad Zubair - Deployable Ultrasound Applicators for MR-guided Thermal Therapy of Pancreatic Tumors
Himanshu Dashora - Clinical trial protocol: Is Expediting Laser Interstitial Thermal Therapy and Chemoradiation for Patients with High-Grade Gliomas Safe?
Shubham Pallod - Multifunctional Skin Sealants For Rapid Approximation, Sealing, and Infection Control
Nooshin Zeinali - Feedback Controlled Microwave Ablation: Preliminary Experimental Studies 
Honoring STM Founding Member, Dr. Bill Dewey
On November 15, 2021 one of the leaders in Hyperthermia, and a founding member of STM and past president (1988), Dr. William C. (Bill) Dewey, passed away.  The first publication on the response of mammalian cells to hyperthermia was presented by Dr. Dewey in 1971. The William C. Dewy award is given every other year to a person who demonstrates excellence in education and mentoring, and this represents one of the ways that we remember Bill with great fondness.
In honor of the many contributions that Dr. Dewey made to the field of Thermal Medicine, and to our Society, we encourage our members to contribute financial donations in his memory. All gifts in Honor of Dr. Dewey will support the educational mission of STM to offer new training opportunities for junior scientists and the importance of guidance and mentoring throughout all of our careers.  
To make your contributions, please email the STM Business office at stm@allenpress.com and one of our staff members will reach out to you to help. You may also make a donation online while renewing your STM membership for 2022 HERE.
Membership - Support STM
NOW is a critical time to show your support for STM and rebuild your connections!
If you have not yet done so, please renew your membership for 2022 here: https://www.thermaltherapy.org/ebusSFTM/MEMBERSHIP.aspx
Membership in The Society for Thermal Medicine is open to anyone interested in the study of thermal medicine.
Membership rights and privileges include:
  • Participating in society elections
  • Committee service
  • Access to restricted “members-only” areas of the STM website
  • Discount on registration fees to the May 2022 STM Virtual Conference
  • Discount on registration fees to the Fall 2022 STM In-Person Mini-Conference and Retreat
  • Free registration to all STM webinars/mini-symposia (includes access to recorded webinars/symposia)
  • A 30% discount on IJH article submission fees 
  • Access to our Monthly Newsletter
  • Career development opportunities such as grant writing/mentorship and participating in diversity/inclusivity/women in science initiatives
Connect with us!
If you have suggestions for how we can better improve STM as we delve together into these new plans, please reach out, and let us know:
International Journal of Hyperthermia updates and higlighted articles
Journal Update
The IJH submission rate has declined over the past year despite having the highest impact factor in journal history (3.916).  Prospective authors are encouraged to check out the updated IJH metrics, including citation metrics, impact factor (3.914 for 2020!), number of downloads, and review times: https://www.tandfonline.com/action/journalInformation?show=journalMetrics&journalCode=ihyt2.
We encourage ALL STM members to take advantage of the 30% discount and submit their high quality manuscripts.  Your home institution library might have a program to alleviate APC costs. We encourage everyone to explore whether their institution has a program that they can take advantage of. 
Editor’s Choice Awards
When you publish with IJH remember to apply to be considered for the Editor’s Choice Awards.  To be eligible, the nominee has to be either a first, or senior, author. They have to be less than 35 years old at the time of submission. There is a cash reward for winners -$750 for each category of Medicine, biology or Physics. Their biography will be published in IJH, and they also receive 1 year free membership to either STM, ESHO or JSTM. 
Upcoming Special Issues
The upcoming special issue for 2023 will be focused on:
Histotripsy
Edited by Suzanne LeBlang and Timothy Ziemlewicz
Deadline for submissions will be announced in Fall 2022
Reminder: IJH is pleased to offer STM members a 30% discount on publication charges!
Do you like learning more about Thermal Medicine? Remember that STM is the official sponsor for the International Journal of Hyperthermia.
IJH is always interested in innovative ideas to increase the breadth of the journal and we strongly hope that the special issues venue will help in the expansion. We are open to additional Industry-Sponsored or Foundation sponsored Special Issues. Please let us know if you have an idea for one!
You can now easily sign up for IJH ‘New Content’ alerts.
Follow the steps below:
1. If you head to the journal homepage, there is a button on the right-hand side of the navigation bar titled “subscribe”:
2. If STM members click on subscribe, two options will then appear:
3. By clicking “New content alerts”, members will be able to log in to the journal website or register, and then set up automated emails to inform them of when content has become available within the journal.
Featured International Journal of Hyperthermia articles
Yao Yang, Hongli Yu, Lingyu Qi, Chenxi Liu, Yuemin Feng, Jianni Qi, Jie Li & Qiang


Published online: 10 March 2022
Views: 379
Objectives
Radiofrequency ablation (RFA) and microwave ablation (MWA) are widely used in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) in clinical practice. We aim to compare the efficacy and safety of TACE combined with RFA or MWA versus TACE monotherapy for intermediate-stage HCC.
Methods
We searched PubMed, Embase, Web of Science, and the Cochrane Library for relevant studies. The outcomes included overall survival (OS), progression-free survival (PFS), local tumor control (LTC) rate, and major complication. Subgroup analysis for different TACE combination therapies was performed.
Results
Ten studies with 1799 patients with intermediate-stage HCC were included. The pooled hazard ratio (HR) for OS was in favor of TACE combination therapy (HR, 0.50, 95% confidence interval [CI], 0.40–0.62). Specifically, the TACE combination therapy was associated with higher 1-, 3-, and 5-year OS rates. Regarding tumor progression, the TACE combination therapy showed significantly better PFS (HR, 0.47, 95% CI, 0.37–0.61) and higher 1-, 2- and 3-year PFS rates than TACE monotherapy. The pooled odds ratio (OR) for the LTC was also in favor of TACE combination therapy (OR, 0.36, 95% CI, 0.24–0.53). No significant difference was found between the two groups regarding the major complication rate (OR, 1.26, 95% CI, 0.74–2.16). These results were consistent across subgroups of TACE + RFA versus TACE and TACE + MWA versus TACE.
Conclusion
TACE combined with RFA or MWA can provide significantly better OS, PFS and LTC than TACE monotherapy for patients with intermediate-stage HCC, without increasing the risk of major complications.
Marcus Beck, Peter Wust, Eva Oberacker, Alexander Rattunde, Tom Päßler, Benjamin Chrzon, Paraskevi Danai Veltsista, Jacek Nadobny, Ruben Pellicer, Enrico Herz, Lukas Winter, Volker Budach, Sebastian Zschaeck & Pirus Ghadjara


Published online: 16 March 2022
Views: 227

Objective
Hyperthermia as an enhancer of radio- and/or chemotherapy has been confirmed by various trials. Quite a few positive randomized trials have been carried out with capacitive hyperthermia systems (CHS), even though specific absorption rates (SAR) in deep regions are known to be inferior to the established annular-phased array techniques. Due to a lack of systematic SAR measurements for current capacitive technology, we performed phantom measurements in combination with simulation studies.
Materials and Methods
According to the current guidelines, homogeneous and inhomogeneous agarose phantoms were manufactured for the commercial CHS Celsius42. Temperature/time curves were registered, and specific absorption rate (SAR) profiles and distributions were derived using the temperature gradient method. We implemented models for electrodes and phantom setups for simulation studies using Sim4Life.
Results
For a standard total power of 200 W, we measured effective SAR until depths of 6–8 cm in a homogeneous phantom, which indicates fair heating conditions for tumor diseases in superficial and intermediate depths. A fat layer of 1 cm strongly weakens the SAR, but 10–20 W/kg are still achieved in intermediate to deep regions (2–10 cm). In the phantom setup with integrated bone, we measured low SAR of 5–10 W/kg in the cancellous bone. Our simulations could fairly describe the measured SAR distributions, but predict tendentially higher SAR than measured. Additional simulations suggest that we would achieve higher SAR with vital fatty tissue and bone metastases in clinical situations.
Conclusion
Capacitive systems are suitable to heat superficial and medium-deep tumors as well as some bone metastases, and CHS application is feasible for a specific class of patients with pelvic and abdominal tumors. These findings are consistent with positive clinical studies.
Hongmin Zeng, Maoyu Liu, Linlin Xiao, Xiaoyuan Zhang, Qing Feng & Shufang Chang


Published online: 21 March 2022
Views: 197

Purpose
To investigate the safety, efficacy, and the immune responses of focused ultrasound in cervical intraepithelial neoplasia (CIN).
Methods
Patients with biopsy-confirmed CIN were recruited for focused ultrasound treatment and asked to return during 3–6 and 6–12 months post-treatment to receive cervical cytology, high-risk human papilloma virus (HPV) detection, and colposcopy. The effective rate was evaluated within 3–6 months, whereas the recurrence rate was evaluated within 6–12 months. Cervicovaginal lavage and cervical tissue were sampled before and 3–6 months after treatment. The expression of interferon gamma (IFN-γ), endoplasmic reticulum aminopeptidase 1 (ERAP1), human leucocyte antigen I (HLA-I), cluster of differentiation 4 (CD4), and cluster of differentiation 8 (CD8) in the cervical tissue were observed by immunohistochemistry. Immunoglobulin A (IgA) and interleukin 10 (IL-10) levels in the cervicovaginal lavage were detected by enzyme-linked immunosorbent assay. Comparisons were made in immune analyte levels before and after treatment.
Results
We analyzed the results of 154 patients. The effective rate at 3–6 months was 96.8%. The recurrence rate at 6–12 months was 2.0%. The eradication rate of HPV was 72.4% at 3–6 months and 81.0% at 6–12 months. No serious adverse reactions and complications were observed. After treatment, a higher expression of ERAP1 was observed (p < 0.05). Significant down-regulation of IgA and IL-10 were detected (each p < 0.05). However, the expression of CD4, CD8, HLA-I, as well as the release of IFN-γ, did not reach statistical significance (each p > 0.05).
Conclusions
Focused ultrasound is an effective and safe therapy for treating CIN, which could improve the local immune milieu of the cervix to some extent.
Twitter Facebook Instagram LinkedIn
STM Business Office | PO Box 7065 | Lawrence, KS 66044-1897 USA
powered by emma